VASCO study (Vaccine Study COvid-19)
- Conditions
- Covid-19
- Registration Number
- NL-OMON26317
- Lead Sponsor
- Dutch Ministry of Welfare and Sports
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 50000
Inclusion Criteria
Community dwelling adult between 18-79 years
- Informed consent provided
- Be able to read, understand and write Dutch
Exclusion Criteria
- Not able or willing to understand and sign the informed consent
- Not able to fill out a digital (app) questionnaire
- Persons living in an institution (e.g. elderly care home, nursing home)
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary endpoint is time to first symptomatic SARS-CoV-2 infection, determined by a positive PCR or antigen test in combination with COVID-19 related symptoms. Those infections can be detected through the national testing programme.
- Secondary Outcome Measures
Name Time Method Secondary endpoints that will be investigated:<br>- SARS-CoV-2 infections by disease severity: COVID-19 related death, COVID-19 related hospitalization, mild SARS-CoV-2 infection, asymptomatic SARS-CoV-2 infection<br>- Unsolicited adverse events for which medical attention was sought